INTRODUCING CG1.4
CG1.4 is designed to treat various inflammatory and autoimmune diseases by inhibiting the production of TNF and other proinflammatory cytokines at their source. This differs from current biologics, which attempt to completely block only TNF after its production. However, TNF has several positive effects in the body which are also blocked by biologic drugs. By addressing inflammation more comprehensively, but not completely blocking the effects of TNF, CG1.4 is designed to offer similar health benefits to biologics while reducing the risk of the serious side effects tied to broader immune suppression, including impacts on cancer defense and neurological health. As an orally administered medication, CG1.4 offers greater convenience with significantly reduced risk and a lower cost compared to injectable biologics.
RADyX'S FIRST POLYMOLECULAR DRUG CANDIDATE
Driven by a Mission
Radyx’s team is a diverse group of innovators, each driven by a shared passion to improve patients' quality of life. We bring our unique skills and perspectives together to push the boundaries of polymolecular drug development, creating therapies that aim to address the complexities of chronic disease without the burden of harmful side effects.
Shaping the Future of Healthcare
Learn more
Partners in Innovation
Partners in Innovation
Invest in a company pioneering a new approach to autoimmune disease treatment. Every investment helps bring patients closer to a safer, more effective option than what exists today. Join us at a pivotal moment in that journey.
Invest in a brighter future
Invest in a brighter future
Join us
Join us
